Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M, Mori T, Sakura T, Tanaka M, Sakai M, Taguchi J, Kurakawa M, Maruta A, Okamoto S, Sakamaki H; Kanto Study Group of Cell Therapy. Kanda Y, et al. Among authors: onoda m. Am J Hematol. 2006 Nov;81(11):838-44. doi: 10.1002/ajh.20710. Am J Hematol. 2006. PMID: 16888784 Free article.
Secondary solid tumors after allogeneic hematopoietic SCT in Japan.
Yokota A, Ozawa S, Masanori T, Akiyama H, Ohshima K, Kanda Y, Takahashi S, Mori T, Nakaseko C, Onoda M, Kishi K, Doki N, Aotsuka N, Kanamori H, Maruta A, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Yokota A, et al. Among authors: onoda m. Bone Marrow Transplant. 2012 Jan;47(1):95-100. doi: 10.1038/bmt.2011.23. Epub 2011 Feb 28. Bone Marrow Transplant. 2012. PMID: 21358690
Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.
Tanaka M, Kanamori H, Matsumoto K, Tachibana T, Numata A, Ohashi K, Kobayashi T, Nakaseko C, Kanda Y, Yamazaki E, Fujisawa S, Ooi J, Sakura T, Aotsuka N, Onoda M, Machida S, Kato J, Usuki K, Watanabe R, Taguchi J, Yano S, Saito T, Takahashi S, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy. Tanaka M, et al. Among authors: onoda m. Bone Marrow Transplant. 2015 May;50(5):727-33. doi: 10.1038/bmt.2015.17. Epub 2015 Mar 2. Bone Marrow Transplant. 2015. PMID: 25730191 Clinical Trial.
Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K, Fujisawa S, Doki N, Kobayashi T, Mori T, Usuki K, Tanaka M, Fujiwara S, Kako S, Aoyama Y, Onoda M, Yano S, Gotoh M, Kanamori H, Takahashi S, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Motohashi K, et al. Among authors: onoda m. Leuk Lymphoma. 2018 Jun;59(6):1332-1337. doi: 10.1080/10428194.2017.1387913. Epub 2017 Oct 16. Leuk Lymphoma. 2018. PMID: 29032731
Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation.
Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S. Shimizu R, et al. Among authors: onoda m. Ann Hematol. 2019 Jul;98(7):1781-1783. doi: 10.1007/s00277-019-03717-8. Epub 2019 May 22. Ann Hematol. 2019. PMID: 31119366 No abstract available.
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant.
Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: onoda m. Bone Marrow Transplant. 2019 Dec;54(12):2020-2026. doi: 10.1038/s41409-019-0585-2. Epub 2019 Jun 11. Bone Marrow Transplant. 2019. PMID: 31186516
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, Onizuka M, Koda Y, Kato J, Takeda Y, Hino Y, Mishina T, Sakaida E, Shono K, Nagao Y, Yokota A, Matsumoto K, Morita K, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Kikuchi T, et al. Among authors: onoda m. Int J Hematol. 2021 Jan;113(1):128-133. doi: 10.1007/s12185-020-02990-y. Epub 2020 Sep 4. Int J Hematol. 2021. PMID: 32886279
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y. Sugiura I, et al. Among authors: onoda m. Blood Adv. 2022 Jan 25;6(2):624-636. doi: 10.1182/bloodadvances.2021004607. Blood Adv. 2022. PMID: 34516628 Free PMC article. Clinical Trial.
Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.
Ohwada C, Yamazaki S, Shono K, Kayamori K, Hino Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Iseki T, Onoda M, Yokota A, Suzuki T, Ishii I, Nakaseko C, Sakaida E. Ohwada C, et al. Among authors: onoda m. Int J Hematol. 2021 Dec;114(6):664-673. doi: 10.1007/s12185-021-03188-6. Epub 2021 Sep 14. Int J Hematol. 2021. PMID: 34523110
241 results